>> 全站文章索引 >> 第43页:
  • ffects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow - [David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM.]
  • Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the wistar rat - [Eamond D. O'Loinsigh, Gerard Boland, John P. Kelly and Kathy M. O'Boyle]
  • Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine:a comparison with their abilities to evoke monoamine release - [Bermack JE, Debonnel G.]
  • Abstracts of the 2003 North American Congress of Clinical Toxicology Annual Meeting - [.]
  • An open study of paroxetine in hypochondriasis - [Desiree B. Oosterbaan, Anton J. L. M. Van Balkom, Christine A. Van Boeijen, Tim GJ De Meij and Richard van Dyck]
  • Reduced (±)-3,4-methylenedioxymethamphetamine (“Ecstasy”) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro - [Yamini Ramamoorthy, Ai-ming Yu, Nina Suh, Robert L. Haining, Rachel F. Tyndale and Edward M. Sellers]
  • Quantitative Analysis for Estimating Binding Potential of the Brain Serotonin Transporter With [11C]McN5652 - [Yoko Ikoma*,?,?, Tetsuya Suhara?,?, Hinako Toyama§, Tetsuya Ichimiya?,?, Akihiro Takano?,?, Yasuhiko Sudo?,?, Makoto Inoue?,?, Fumihiko Yasuno?,? and Kazutoshi Suzuki?,?]
  • British drug company to put data online as criticism mounts - [Jim Giles]
  • Is A Single Dose of MDMA Harmless - [Franz X Vollenweider, Alex Gamma, Matthias Liechti, Theo Huber]
  • Hypothalamic–pituitary–adrenal(HPA) system activity in depression and infection with Borna disease virus and Chlamydia pneumoniae - [M Deuschle, L Bode, P Schnitzler, U Meyding-Lamad??, A Plesch, H Ludwig, B Hamann, I Heuser]
  • Spitzer sues drug giant for deceiving doctors - [Meredith Wadman]
  • Method of treatment must be specific - [.]
  • Response☆ - [Pierre Blier, Julie Turcotte, Chantal H??bert, Guy Debonnel]
  • The pharmacogenomics of depression - [J Licinio, M-L Wong]
  • a question of silence - [.]
  • Disclosure of Clinical Trials in Children - [Maurizio Bonati, Chiara Pandolfini, and Antonio Clavenna]
  • FDA Weighs Suicide Risk in Children on Antidepressants - [Constance Holden]
  • Reward for Persistence in Substance P Research - [Claes Wahlestedt]
  • Cognitive Inflexibility After Prefrontal Serotonin Depletion - [H. F. Clarke, J. W. Dalley, H. S. Crofts, T. W. Robbins, and A. C. Roberts]
  • DRUG SAFETY:Conflict-of-Interest Allegations Derail Inquiry Into Antidepressant's 'Dark Side' - [Daniel Bachtold]
  • Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors - [Mark S. Kramer, Neal Cutler, John Feighner, Ram Shrivastava, John Carman, John J. Sramek, Scott A. Reines, Guanghan Liu, Duane Snavely, Edwina Wyatt-Knowles, Jeffrey J. Hale, Sander G. Mills, Malcolm MacCoss, Christopher J. Swain, Timothy Harrison, Raymon]
  • Tough Placebo Rules LeaveScientists Out in the Cold - [Cassio Leite Vieira]
  • Future Brightening for Depression Treatments - [Constance Holden]
  • The Medication Merry-Go-Round - [Kathryn Brown]
  • Phosphorylation and Sequestration of Serotonin Transporters Differentially Modulated by Psychostimulants - [Sammanda Ramamoorthy and Randy D. Blakely]
  • Out in the open - [.]
  • Anxiety disorders and risk for suicide attempts findings from the Baltimore Epidemiologic Catchment area follow-up study - [Bolton JM, Cox BJ, Afifi TO, Enns MW, Bienvenu OJ, Sareen J.]
  • Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline - [A John Rush1 MD, Madhukar H Trivedi1 MD, Thomas J Carmody2 Ph.D, Rafe M J Donahue3 Ph.D, Trisha L Houser3 BA, Carolyn Bolden-Watson3 Ph.D, Sharyn R Batey4 Pharm.D, John A Ascher4 MD and Alan Metz3 MDD:1Department of Psychiatry, University of Texas Southwe]
  • Which factors are important predictors of non-recovery from major depression? A 2-year prospective observational study - [Viinam?ki H, Haatainen K, Honkalampi K, Tanskanen A, Koivumaa-Honkanen H, Antikainen R, Valkonen-Korhonen M, Hintikka J.]
  • Optic Neuritis - [Atkins EJ, Biousse V, Newman NJ.]
  • Opioids in pain management of blood-related malignancies - [Niscola P, Scaramucci L, Romani C, Giovannini M, Maurillo L, del Poeta G, Cartoni C, Arcuri E, Amadori S, De Fabritiis P.]
  • The -Opioid Receptor Agonist (+)BW373U86 Regulates BDNF mRNA Expression in Rats - [Mary M Torregrossa1, Ceylan Isgor2, John E Folk3, Kenner C Rice3, Stanley J Watson1,2 and James H Woods1,4]
  • Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases - [Ali Saffet Gonul, Fisun Akdeniz, Ozlem Donat and Simavi Vahip]
  • Effect of Antidepressant Drugs in Mice Lacking the Norepinephrine Transporter - [Marta Dziedzicka-Wasylewska1, Agata Faron-Górecka1, Maciej Kumider1, Elbieta Drozdowska1, Zofia Rogó1, Joanna Siwanowicz1, Marc G Caron2 and Heinz B?nisch3]
  • Perospirone augmentation of paroxetine in treatment of refractory obsessive–compulsive disorder with depression - [Tatsui Otsuka, Takashi Togo, Naoya Sugiyama, Kumi Uehara, Asuka Yoshimi, Aya Karashima, Hiromi Shioya and Yoshio Hirayasu]
  • Diagnosis and treatment of obsessive-compulsive disorder and related disorders - [Dell]
  • Temperature Regulation in Depression: Functional 5HT1A Receptor Adaptation Differentiates Antidepressant Response - [Jeffrey L Rausch1, Maria E Johnson1, Katherine E Kasik1 and Stephen M Stahl2]
  • Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression - [Jantien P. Brouwer, Bente C. Appelhof, Elisabeth F.C. van Rossum, Jan W. Koper, Eric Fliers, Jochanan Huyser, Aart H. Schene, Jan G.P. Tijssen, Richard Van Dyck, Steven W.J. Lamberts, et al.]
  • Open-label trial of paroxetine in children with obsessive-compulsive disorder - [Rasim Somer Diler and Ayse Avci]
  • Reversal of Inappropriate Peripheral Vascular Responses in Hypertrophic Cardiomyopathy - [Rajesh Thaman, Perry M. Elliott, Jaymin S. Shah, Bryan Mist, Lynne Williams, Ross T. Murphy, William J. McKenna and Michael P. Frenneaux]
  • Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation - [Juza Chen, Nicola J. Mabjeesh, Haim Matzkin and Alexander Greenstein]
  • DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats - [Gook Jun Ahn, Kyung Koo Kang, Dong Sung Kim, Byoung Ok Ahn, Won Bae Kim, Sung Keun Kang, Byeong Chun Lee and Woo Suk Hwang]
  • Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: Post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials - [David L. Dunner, Alan Lipschitz, Cornelius D. Pitts and John T. Davies]
  • St John's wort for depression Time for a different perspective - [Pilkington K, Boshnakova A, Richardson J.]
  • Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry review of studies in new drug applications - [Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B.]
  • Is Drug Therapy for Urinary Incontinence Used Optimally in Long-Term Care Facilities - [Narayanan S, Cerulli A, Kahler KH, Ouslander JG.]
  • Randomised controlled trial of problem solving treatment,antidepressant medication - [Mynors-Wallis LM, Gath DH, Day A, Baker F.]
  • Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care - [Oxford University Department of Psychiatry, Warneford Hospital, Oxford OX3 7BJ. lmmw@soton.ac.uk]
  • Religiosity of depressed elderly inpatients - [Payman V, George K, Ryburn B.]
  • Hippocampal atrophy in systemic lupus erythematosus - [Appenzeller S, Carnevalle AD, Li LM, Costallat LT, Cendes F.]
  • Social adjustment based on reported behaviour in bipolar affective disorder - [Morriss R, Scott J, Paykel E, Bentall R, Hayhurst H, Johnson T.]
  • Early identification and high-risk strategies for bipolar disorder - [Correll CU, Penzner JB, Lencz T, Auther A, Smith CW, Malhotra AK, Kane JM, Cornblatt BA.]
  • Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression - [Paola Rocca, Concetta De Leo, Carola Eva, Livio Marchiaro, Anna Maria Milani, Rita Musso, Luigi Ravizza, Enrico Zanalda and Filippo Bogetto]
  • Functional impairment in patients with mania baseline results of the EMBLEM study - [Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E; EMBLEM Advisory Board.]
  • Manic symptoms and impulsivity during bipolar depressive episodes - [Swann AC, Gerard Moeller F, Steinberg JL, Schneider L, Barratt ES, Dougherty DM.]
  • A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia - [Cornelius L. E. Katona, Professor of Psychiatry of the Elderly 1 *, Brian N. Hunter 2, Julia Bray 2 AD:1Department of Psychiatry and Behavioural Sciences,UCL Medical School, London, UK2SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (South)]
  • Comorbid cannabis use and panic disorder: short term and long term follow-up study - [Pinhas N. Dannon 1 2 3 *, Katherine Lowengrub 1 3, Revital Amiaz 2, Leon Grunhaus 2, Moshe Kotler 3 AD:1Rehovot Community Mental Health Care and Rehabilitation Centre, Israel2Chaim Sheba Med Centre, Psychiatry Ward, Tel Hashomer, Israel3Beer Ya]
  • Personality disorders and response to medication treatment in panic disorder: A 1-year naturalistic study - [Carlo Marchesi, Chiara De Panfilis, Alessandro Cantoni, Stefania Fontò, Maria R. Giannelli and Carlo Maggini]
  • Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial - [D.G.S. Perahia, F. Wang, C.H. Mallinckrodt, D.J. Walker and M.J. Detke]
  • social anxiety and insomnia the mediating role of depressive symptoms - [Buckner JD, Bernert RA, Cromer KR, Joiner TE, Schmidt NB.]
  • Anxiety disorders in the 21st century status, challenges, opportunities, and comorbidity with depression - [Devane CL, Chiao E, Franklin M, Kruep EJ.]
  • Effect of treatment of panic disorder in patients with frequent ICD discharges: a pilot study - [P. M. J. C. Kuijpers, A. Honig and H. J. J. Wellens]
  • The effect of 4 weeks treatment with desloratadine (5 mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis - [Tworek D, Bocheńska-Marciniak M, Kupczyk M, Górski P, Kuna P.]
  • Nonepileptic Uses of Antiepileptic Drugs in Children and Adolescents - [Golden AS, Haut SR, Moshé SL.]
  • Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents - [Raz Yirmiya1 Ph.D, Yehuda Pollak1 MA, Ohr Barak1 MA, Ronit Avitsur1 Ph.D, Haim Ovadia2 Ph.D, Michael Bette3 Ph.D, Eberhard Weihe3 MD and Joseph Weidenfeld2 Ph.D]
  • Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling - [J. Landgrebe, G. Welzl, T. Metz, M. M. van Gaalen, H. Ropers, W. Wurst and F. Holsboer]
  • Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze - [Dominique Drapier, Danièle Bentué-Ferrer, Bruno Laviolle, Bruno Millet, Hervé Allain, Michel Bourin and Jean-Michel Reymann]
  • Salmon calcitonin potentiates the analgesia induced by antidepressants - [María Jesús Ormazábal, Carlos Goicoechea, Eva Sánchez and María Isabel Martín]
  • A review of the safety of selective serotonin reuptake inhibitors during pregnancy - [David J. Goldstein 1 2 3 *, Karen Sundell 1 AD:1Neuroscience Division, Lilly Research Laboratories, Lilly Corporate Center-1730, Indianapolis, IN 46285, USA2Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis, IN, US]
  • Pharmacological Treatment of Adolescent Major Depression - [David Cohen, Priscille Gerardin, Philippe Mazet, Diane Purper-Ouakil, Martine F. Flament]
  • Higher Cortisol Levels Following Exposure to Traumatic Reminders in Abuse-Related PTSD - [Bernet M Elzinga1, Christian G Schmahl2, Eric Vermetten3, Richard van Dyck4 and J Douglas Bremner5,6,7]
  • The four-plates test-retest paradigm to discriminate anxiolytic effects. - [Ripoll N, Nic Dhonnchadha BA, Sebille V, Bourin M, Hascoet M]
  • Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity - [P. Sargent, D. J. Williamson, G. Pearson, J. Odontiadis, P. J. Cowen]
  • Antidepressant medication use and breast cancer risk: a case-control study - [Allan Steingart, Michelle Cotterchio, Nancy Kreiger, Margaret Sloan]
  • Social Impulsivity Inversely Associated with CSF 5-HIAA and Fluoxetine Exposure in Vervet Monkeys - [Lynn A Fairbanks1 Ph.D, William P Melega1,2 Ph.D, Matthew J Jorgensen1 Ph.D, Jay R Kaplan3 Ph.D and Michael T McGuire1,4 MD]
  • Postural hypotension induced by paroxetine - [C Andrews, G Pinner]
  • A direct entry to substituted piperidinones from α,β-unsaturated amides by means of aza double Michael reaction - [Kiyosei Takasu, Naoko Nishida and Masataka Ihara]
  • Improved sample preparation for the quantitative analysis of paroxetine in human plasma by stable isotope dilution negative ion chemical ionisation gas chromatography–mass spectrometry - [Hans J?rg Leis, Werner Windischhofer and Günter Fauler]
  • Determination of paroxetine in geriatric depression by high-performance liquid chromatography - [Isis A. Zainaghi, Vera L. Lanchote and Regina H. C. Queiroz]
  • Selective serotonin reuptake inhibitors in sewage influents and effluents from Troms?, Norway - [Terje Vasskog, Urs Berger, Per-Jostein Samuelsen, Roland Kallenborn and Einar Jensen]
  • Clinical and biological aspects of anti-P-ribosomal protein autoantibodies - [Toubi E, Shoenfeld Y.]
  • Antibody induction of lupus-like neuropsychiatric manifestations - [Lawrence DA, Bolivar VJ, Hudson CA, Mondal TK, Pabello NG]
  • A Mathematical Model for Paroxetine Antidepressant Effect Time Course and Its Interaction with Pindolol - [Berangere Gruwez, Alain Dauphin, Michel Tod]
  • Seasonal variations in the binding of [3H]paroxetine to the platelet serotonin transporter sites in African-American cocaine-dependent patients and healthy volunteers - [Ashwin A. Patkar 1 *, Wade H. Berrettini 2, Allan Lundy 1, Heather W. Murray 1, Kevin P. Hill 1, Michael J. Vergare 1, Stephen P. Weinstein 1 AD:1Division of Substance Abuse Programs, Department of Psychiatry and Human Behavior, Thomas Jefferson Universit]
  • The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test - [Martine Hasco?t, Michel Bourin and Brid A. Nic Dhonnchadha]
  • Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients - [Wendy Chrapko1, Paul Jurasz2,4, Marek W Radomski2,4, Stephen L Archer3, Stephen C Newman1, Glen Baker1, Nathalie Lara1 and Jean-Michel Le Mellédo1]
  • Brain neurosteroid changes after paroxetine administration in mice - [Allon Nechmad, Rachel Maayan, Baruch Spivak, Edward Ramadan, Michael Poyurovsky and Abraham Weizman]
  • Teaching Systems-Based Practice to Primary Care Physicians to Foster Routine Implementation of Evidence-Based Depression Care - [Sherman SE, Fotiades J, Rubenstein LV, Gilman SC, Vivell S, Chaney E, Yano EM, Felker B.]
  • Presence and Characterization of the Serotonin Transporter in Human Resting Lymphocytes - [Donatella Marazziti MD, Alessandra Rossi Dr Biol.Sci, Gino Giannaccini Dr Biol.Sci, Stefano Baroni Dr Biol.Sci, Antonio Lucacchini Dr Biol.Sci and Giovanni B Cassano MD, FRCP]
  • Antihyperalgesic effects of cizolirtine in diabetic rats: behavioral and biochemical studies - [Bertrand Aubel, Valérie Kayser, Annie Mauborgne, Antonio Farré, Michel Hamon and Sylvie Bourgoin]
  • Use of antidepressant medications in relation to the incidence of breast cancer - [D Fulton-Kehoe1,2, M A Rossing2,3, C Rutter4, M T Mandelson3,4 and N S Weiss2,3]
  • Delayed pharmacological effects of antidepressants - [A Frazer1,2 and S Benmansour1]
  • 糖尿病合并神经精神疾病的文献学研究 - [.]
  • Functional and well-bejng outcomes of patients with depression compared with chronic general medical illnesses - [HAYS RD， WELLS KB， SHERBOURNE CD， ROGERS W， SPRITZER K]
  • The prevalence of comorbid depression in adults with diabetes - A meta-analysis - [Anderson RJ， Freedland KE， Clouse RE， Lustman PJ]
  • The regulation of adipose tissue distribution in humans - [Bjorntorp P]
  • Depression and diabetes - Impact of depression symptoms on adherence， function， costs - [Ciechanowski PS， Katon WJ， Russo JE]
  • Depression and poor glycemic control - A meta-analytic review of the literature - [Lustman PJ， Anderson RJ， Freedland KE， de Groot M， Carney RM， Clouse RE]
  • Psoriasis causes as much disability as other major medical diseases - [Rapp SR， Feldman SR， Exum ML， Fleischer AB， Reboussin DM]
  • Depression and risk for onset of type II diabetes - A prospective population-based study - [Eaton WW， Armenian H， Gallo J， Pratt L， Ford DE]


    • 分页: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
    41 42 [43] 44 45 46 47 48 49 50